GlobeNewswire Inc.··NaPraxis Precision Medicines Posts Breakthrough Results for Rare Epilepsy Gene Therapy
Praxis reports 77% placebo-adjusted seizure reduction in SCN2A epilepsy treatment with no serious safety events, advancing precision neurotherapy.
PRAXIONSclinical trialprecision medicine